The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia

Authors: Jessica Brown1*, Luisa Iacovelli2*, Gabriele Di Cicco2, Ben Grayson1, Lauren Rimmer1, Jennifer Fletcher1, Joanna C. Neill1, Mark J. Wall3, Richard T. Ngomba4#, Michael Harte1#.

1. Division of Pharmacy & Optometry, University of Manchester, M13 9PT, UK; 2. Department of Physiology and Pharmacology "V. Erspamer" Sapienza University of Rome, Italy; 3. School of Life Sciences, University of Warwick, CV4 7AL; 4. School of Pharmacy, University of Lincoln, LN6 7DL, UK.

* first Co-Authors and # last Co-Authors
§Address correspondence to:
¶Dr. Richard T Ngomba: University of Lincoln, School of Pharmacy, College of science, Joseph Banks Laboratories; LN6 7DL, UK. e-mail: richardngomba@hotmail.com (rngomba@lincoln.ac.uk)

Highlights

- mGluR5 PAMs VU0409551 and VU0360172 reverse cognitive deficits in the scPCP model
- Elevated PFC p-AKT and p-MAPK expression in scPCP rats was lowered by mGluR5 PAMs
- p-AKT and p-MAPK expression was reduced by VU0409551 and VU0360172, respectively
Abstract

The metabotropic glutamate receptor mGlu5 has been implicated in the neuropathology of several debilitating disorders. In schizophrenia, mGlu5 receptor hypofunction has been linked with neuropathology and cognitive deficits, making it an attractive therapeutic target. The cognitive impairment associated with schizophrenia remains an unmet clinical need, with existing antipsychotics primarily targeting positive symptoms and failing to induce consistent, substantial improvements in cognition, thus providing incomplete treatment. Using the sub-chronic phencyclidine (scPCP) rat model, widely shown to mimic the cognitive impairment and neuropathology of schizophrenia, we have investigated two mGlu5 receptor positive allosteric modulators (PAMs), VU0409551 and VU0360172. We compared the efficacy of these compounds in restoring cognitive deficits and, since these two PAMs have reportedly distinct signalling mechanisms, changes in mGlu5 receptor signalling molecules AKT and MAPK in the prefrontal cortex. Although not effective at 0.05 and 1mg/kg, cognitive deficits were significantly alleviated by both PAMs at 10 and 20 mg/kg. The compounds appeared to have differential effects on the scPCP-induced increases in AKT and MAPK phosphorylation: VU0409551 induced a significant decrease in expression of p-AKT, whereas VU0360172 had this effect on p-MAPK levels. Thus, the beneficial effects of PAMs on scPCP-induced cognitive impairment are accompanied by at least partial reversal of scPCP-induced elevated levels of p-MAPK and p-AKT, dysfunction of which is strongly implicated in schizophrenia pathology. These promising data imply an important role for mGlu5 receptor signalling pathways in improving cognition in the scPCP model and provide support for mGlu5 receptor PAMs as a possible therapeutic intervention for schizophrenia.

Key words

mGluR5; Schizophrenia; Phencyclidine (PCP); Cognition; Rat; VU0409551; VU0360172; animal model
1. Introduction

Group I metabotropic glutamate receptors (mGlu1 and mGlu5) have diverse actions including the modulation of neuronal function, synaptic transmission, synaptic plasticity, cell differentiation and survival. mGlu5 receptors are coupled to Gαq/11, and activate phospholipase C to produce inositol-1,4,5-triphosphate (IP3) and DAG, leading to the mobilization of intracellular calcium (Abe et al., 1992). This in turn activates PKC, PLA2, MAPK and downstream modulation of a number of ion channels (Hermans and Challiss, 2001; Conn et al., 2009; Ribeiro et al., 2010). Agonist stimulation of mGlu5 receptors also leads to the phosphorylation and hence activation of different MAPK pathways such as ERK1/2 MAPK (Thandi et al., 2002; Hu et al., 2007) and p38 MAPK (Peavy and Conn, 1998; Rush et al., 2002). This increases expression of specific transcription factors including Elk-1, cAMP response element binding-protein and c-Jun. These regulate the expression of several genes including those involved in long-term depression (LTD) such as Arc (Rush et al., 2002; Gallagher et al., 2004; Wang et al., 2007). mGlu5 receptor stimulation also activates the phosphatidylinositol-3-kinase (PI3K) pathway, inducing Akt phosphorylation and activation of the mammalian target of rapamycin (mTOR) which have also been implicated in producing LTD (Chan et al., 1999; Hou and Klann, 2004). The relative contribution of each pathway upon mGluR5 stimulation is highly context specific, depending on cell or tissue that are the object of investigation. Furthermore, the identification of the so called “biased agonists”, drugs that are able to stimulate a selected signalling pathway, provide a promising tool to modulate receptor induced responses in a more selective way (Trinh et al., 2018). In disease states such as epilepsy and pain the balance between mGlu5 receptor signalling transduction pathways can be perturbed and appear to contribute to the pathology. In schizophrenia, there is considerable evidence linking mGlu5 receptor hypofunction to the pathophysiology, with mGluRs a possible target for treatment (Wang et al., 2020).

Schizophrenia is a chronic, heterogeneous and debilitating psychiatric illness characterised by a multitude of symptoms (Stepnicki et al., 2018). Whilst positive symptoms are often reasonably well-treated by existing antipsychotic medications, no consistent, substantial improvement in cognition has been reported with these pharmacotherapies (O’Grada and Dinan, 2007; Harvey and McClure, 2006; Keefe and Harvey, 2012). The lack of therapeutic interventions targeting cognitive dysfunction and negative symptoms may explain why patients often show incomplete functional recovery (Schulz and Murray, 2016). Specifically, cognitive deficits in attention, working memory, processing speed and verbal/visual learning (alongside negative symptoms such as lack of motivation and asociality) are closely associated with quality of life and long-term functional outcomes (Harvey et al., 2006; Savilla et al., 2008; Tsapakis et al., 2015; Green 1996; Tripathi et al., 2018; Neill et al., 2014). Despite a considerable amount of effort to develop therapeutic strategies for the cognitive impairment associated with schizophrenia (CIAS), no pharmacological agent has yet received a licence to treat this condition, making it an important unmet clinical need.
One of the major hypotheses for the pathogenesis of schizophrenia is NMDAR hypofunction, which is supported by many lines of evidence including the effects of NMDAR antagonists, such as phencyclidine (PCP) and ketamine, which produce cognitive dysfunction and psychosis in humans. Since there is a functional cross-talk between mGlu5 and NMDA receptors, with mGlu5 facilitating NMDA receptor function, and evidence for mGlu5 hypofunction, there has been considerable interest in the mGlu5 receptor as a therapeutic target in schizophrenia (Nicoletti et al., 2019; Su et al., 2021). Furthermore, knock out of the mGlu5 receptor in mice leads to changes in schizophrenia related genes (Luoni et al., 2018). One approach has been to use activity-dependent positive allosteric modulators (PAMs) bind to an allosteric site on the mGlu5 receptor to enhance the effects of glutamate but do not activate the receptors themselves (Sengmany et al., 2017). These mGlu5 receptor PAMs display different intracellular mechanisms in both cell lines and dissociated cortical neurons, which may account for the differences in their effects observed in vivo (Sengmany et al., 2017). It has been shown that mGlu5 receptor PAMs correct the negative and cognitive symptoms exhibited by amphetamine- and PCP-treated animal models whilst avoiding sedative side effects (Matosin et al., 2013; Gilmour et al., 2013; Parmentier-Batteur et al., 2012). Newer PAMs have been discovered which do not appear to modulate NMDA receptor function (Rook et al., 2015; D’ Amore et al., 2013) but are effective in psychosis. For example, the mGlu5 receptor PAMs VU0409551 and VU0360172 exhibit in vivo efficacy in acute psychosis models (Rodriguez et al., 2010; Rook et al., 2015). Moreover, application of VU0409551 in the serine racemase (SR) knockout mouse model of NMDAR hypofunction induced cognitive improvements without NMDAR potentiation and excitotoxicity (Balu et al., 2016; Maksymetz et al., 2017; Rook et al., 2015).

Based on the pioneering work of Jentsch and Roth (1999), we have developed a preclinical model for CIAS using a subchronic dosing regimen of phencyclidine (PCP) in female rats, followed by a minimum washout period of 7 days (Sams-Dodd, 1996; Neill et al., 2010; 2016; Cadinu et al., 2018). This clinically relevant, well-validated model is widely shown to mimic the chronic cognitive impairment and negative symptoms of schizophrenia (Meltzer et al., 2013; Neill et al., 2014, 2016). Cadinu et al. (2018) highlight the underlying neurobiological alterations in scPCP-treated rats, including reduced PFC expression of parvalbumin (PV), the neuronal integrity marker N-Acetylaspartic acid (NAA) and dopamine release.

Here we have used this sub-chronic PCP (scPCP) model to evaluate the actions of two mGlu5 receptor PAMs, VU0360172 and VU0409551. In HEK293 cells stably transfected to express mGlu5 receptors, VU0360172 has been reported to activate both Gαq- and Gβγ-mediated mGlu5 receptor signalling, whereas VU0409551 has been reported to be “biased” as it preferentially stimulates Gαq-mGlu5 receptor signalling (Sengmany et al., 2017). Furthermore, in cortical neurons and cell lines, VU0409551 shows significant bias away from pERK1/2 (relative to IP1) and a lack of agonist efficacy for iCa2+ mobilization compared to VU0360172 (Sengmany et al., 2017) and there are differences in effects on DHPG receptor activation (Hellyer et al., 2019). Although these differences have been observed in vitro it is unclear what effects these compounds will have in vivo.
We examined the efficacy of acute doses of these mGlu5 receptor PAMs in reversing cognitive deficits in the scPCP model. Visual recognition memory was evaluated using the novel object recognition (NOR) test, a robust, replicable, and versatile paradigm with high translational relevance for investigating cognitive dysfunction associated with schizophrenia (Young et al., 2009; Nikiforuk et al., 2013). By assessing the natural preference of an animal for novel stimuli, this paradigm has high ethological relevance, as well as not requiring stressful, potentially confounding elements such as food or water deprivation (Grayson et al., 2015).

Western blot analysis of p-AKT and p-MAPK in the PFC was used to elucidate the mechanistic effects of these PAMs on mGlu5 receptor intracellular signalling pathways. To our knowledge, this is not only the first study to evaluate both the behavioural and neurobiological effects of these compounds in the sub-5 chronic PCP rat model for schizophrenia but is also valuable in its comparison of two notable, for preclinical studies, mGluR5 PAMs with reportedly distinct mechanisms of action upon intracellular signalling pathways.

2. Methods

2.1 Animals

A total of 125 Female Lister Hooded rats (Cohort 1, n = 44; Cohort 2, n = 45; Cohort 3, n = 36; Charles River Laboratories, UK) weighing (220.3g ± 23.8g) at the beginning of the studies, were group housed (4-5 per cage) in GR1800 double-decker individually ventilated cages (38 cm × 59 cm × 24 cm, Techniplast, UK) at 21 ± 1°C, 55 ± 10% humidity on a 12-hour light/dark cycle (lights on at 0700h). Enrichment was provided through the addition of sizzlenest®, cardboard corner homes, and cardboard play tunnels (all Datesand Ltd, UK). Throughout studies, animals had ad libitum access to standard rodent diet pellets (Special Diet Services) and water. All procedures were performed at the University of Manchester, approved by the University of Manchester Animal Welfare and Ethical Review Board (AWERB) and were in compliance with the Home Office Animals (Scientific Procedures) Act 1986.

2.2 Drugs

Phencyclidine (PCP; Sigma, UK); VU0360172 (N-cyclobutyl-6-((3-fluorophenyl)ethynyl)picolinamide; Tocris/ Bio-Techne); VU0409551(4-fluorophenyl)(2-(phenoxyethyl)-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)methanone; Tocris/ Bio-Techne)

2.3 Drug treatments
As summarised in Figure 1, rats were pre-treated with either vehicle (0.9% saline; Cohort 1, n=10; Cohort 2, n=12; Cohort 3, n=6) or sub-chronic phencyclidine, (scPCP, 2 mg/kg; Cohort 1, n=34; Cohort 2, n=33; Cohort 3, n=30) dissolved in 0.9% saline, via the intraperitoneal route (i.p.) twice daily for 7 days, followed by at least 7 days’ washout. scPCP rats were then tested following acute i.p administration (pretreatment time = 90 mins; dose volume 1ml/kg) of VU0409551 or VU0360172 (dissolved in 10% Tween 80 and diluted with 0.9% saline). VU0409551 was administered at 0.05mg/kg (Cohort 1, n=12), 1mg/kg (Cohort 1, n=12; Cohort 3, n=6), 10mg/kg (Cohort 2, n=10; Cohort 3, n=6) or 20mg/kg (Cohort 2, n=10), and VU0360172 at 0.05mg/kg (Cohort 1, n=12), 1mg/kg (Cohort 1, n=12; Cohort 3, n=6), 10mg/kg (Cohort 2, n=10; Cohort 3, n=6) or 20mg/kg (Cohort 2, n=10). Vehicle-treated rats were tested following acute vehicle application (Cohort 1, n=10; Cohort 2, n=12, Cohort 3, n=6). The minimum 1-week washout period after scPCP dosing is necessary to prevent behaviour of the rats being influenced either by direct drug effects or by drug withdrawal effects (Jentsch et al., 1998). In this study, a 6-week washout period of no behavioural testing was used in light of previous work in our laboratory showing that whilst NOR deficits exhibited by scPCP rats are evident in tests conducted both 1 and 6 weeks after treatment cessation, robust reduced parvalbumin expression is only apparent after a 6-week washout period (Abdul-Monim et al., 2007; Leger et al., 2015). The doses of mGlu5 receptor PAMs applied were selected based upon our preliminary investigations implying effectiveness of these compounds in NOR at 10mg/kg, along with previous literature indicating administration of VU0409551 (1-10 mg/kg) to result in a dose-dependent increase in recognition memory in the NOR task, with a MED of 3mg/kg (Rook et al., 2015).

**Insert Figure 1 here**

2.4 Behaviour: Novel Object Recognition paradigm

The NOR test was performed as previously described (Grayson et al., 2007; Neill et al., 2016). Briefly, rats were habituated in cage groups to the empty test box (52 × 52 × 31 cm) and the behavioural test room environment for 20 minutes the day prior to NOR testing. The test consisted of two 3-minute trials separated by a 1-minute inter-trial interval (ITI) in the home cage. The 1-minute ITI incorporated into the NOR protocol served to directly assess PFC-mediated cognitive functions. As demonstrated by Runyan and Dash (2005), short-term storage of information within the PFC for around 1 minute is required to foster cognitive control, dictating behaviour in tasks with conflicts. In the first (acquisition) trial, the animals were introduced to the testing arena and explored two identical objects (A1 and A2). This was followed by the second (retention trial), where animals explored a duplicate familiar object (A) from the acquisition phase (to avoid olfactory trails) and a novel object (B; Figure 1). The position (left/right) and the nature (can/bottle) of the object were randomised among animals to reduce the effects of object and place preference. Post-behavioural testing, the video recordings were scored by an experimenter who was blinded to the treatment groups, using the ‘Jack R Auty Novel Object Recognition Task Timer’. The exploration times of each object (A1, A2, A and B, familiar
and novel) in each trial were recorded, along with the total exploration time of both objects in each trial. Object exploration was defined as animals licking, sniffing or touching the object with the forepaws whilst sniffing, but not leaning against, turning around, standing or sitting on the object (Grayson et al., 2007). Locomotor activity (LMA) across both trials was also measured by the number of marked lines crossed by the base of the tail, along with discrimination index (DI): the difference in exploration time expressed as a proportion of the total time spent exploring both objects. If an animal failed to explore one or both objects (for less than 1 second) in the acquisition or retention trial, it was excluded from the final data analysis.

2.6 Tissue preparation and immunoblotting

To obtain protein expression data that directly corresponds to the behavioural results, animals were culled and brains immediately removed 90 minutes after acute administration of VU0409551, VU0360172 or vehicle (Cohort 3). This was the timepoint of NOR testing in Cohorts 1 and 2. The brain samples were stored at -80°C until dissection that was performed on dry ice. After a slight thawing period, the olfactory bulb was removed. The PFC (identified according to Bregma coordinates +3 to +1.7 mm) was removed, transferred into labelled Eppendorf® tubes and immediately placed on dry ice. The tissue was homogenized by sonication in 10 μl/mg of tissue of Triton X-lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and 10 mM β-glycerophosphate) as described previously (Nardecchia et al., 2018). After protein determination, samples containing 40 μg of protein cell lysates were prepared for SDS-PAGE electrophoresis. Each set of samples was electrophoresed in duplicate onto 2 parallel gels and blotted onto nitrocellulose in order to have 2 identical membranes. The first membrane was cut at around 50 kDa; the upper part was probed with with anti-phospho-AKT (Ser 473) (Cell Signalling Technology BK4060), 1:500; the lower part was probed with anti-phospho-ERK1/2 (Thr202/Tyr204), (Cell Signalling Technology BK4370), 1:500. Similarly, the second membrane was cut at 50 kDa; the upper part was probed with anti-AKT (Cell Signalling Technology BK4691) and the lower part was probed with anti-ERK1/2 (Cell Signalling Technology BK4348). We chose to probe on two identical but separate membranes the anti-phospho antibodies and their total counterpart respectively, as all antibodies were produced in rabbit and stripping procedures could not be used. The immunoreactive bands were visualized by enhanced chemiluminescence (Westar Nova 2011, Bologna, Italy) using horseradish peroxidase-conjugated secondary antibodies. Densitometric analysis of the immunoreactive bands was performed by Image J (NIH, Bethesda, MD, United States).

2.9 Statistical Analysis

All data are expressed as mean ± S.E.M (Cohort 1, n=11-20; Cohort 2, n=8-25; Cohort 3 behavioural data, n=6-30; Cohort 3 signalling data, n=6 per group). NOR test data were analysed by a two-way ANOVA
(factors: drug and exploration time of the two objects) or one-way ANOVA (LMA, DI and total exploration time). Further analysis was conducted via a post-hoc Student’s t-test (time spent exploring the objects) or LSD test (LMA, DI and total exploration time). For Western blot data, a one-way ANOVA was used to compare all groups, using the Tukey’s multiple comparison test. For all data, statistical significance was defined as $P<0.05$.

3. Results

3.1 Novel object recognition (NOR) is disrupted in the sub-chronic PCP (scPCP) model

In this study, NOR was used to measure scPCP-induced cognitive deficits. NOR measures visual recognition memory and was performed halfway through the 6-week washout period post-scPCP dosing. An overall 2-way ANOVA did not reveal a significant interaction between any of the treatments and object exploration during the acquisition phase. In addition, there were no significant differences in the exploration time of 2 identical objects for any group (Figure 1C). In the retention phase, the 2-way ANOVA revealed a significant interaction between treatment and object exploration ($F(1,76)=23.10; P<0.0001$). As expected, scVehicle-treated rats spent significantly more time exploring the novel object compared with the familiar object ($t(76)=6.107; P<0.000001$), whereas rats treated with scPCP showed the expected deficits in the ability to discriminate between novel and familiar objects (Figure 1D). There was also a significant reduction in the discrimination index in the scPCP rats compared with controls ($t(34)=7.257; P<0.000001$; Figure 1E). There was no significant difference in locomotor activity, as assessed by the total number of line crossings across both trials, between the vehicle- and scPCP animals (Fig 1F). Therefore, as previously published (Grayson et al., 2015) there is selective disruption of NOR without changes in locomotion in the scPCP model.

3.2 The effects of the mGlu5 receptor PAMs VU0409551 and VU0360172 on the scPCP-induced NOR deficit

3.21 Cohort 1 (0.05 and 1 mg/kg of PAMs)

We investigated the actions of VU0409551 or VU0360172 on NOR deficits in the scPCP model. Behavioural testing was initially performed following acute administration of low doses (0.05 and 1 mg/kg) of either VU0409551 or VU0360172. Although it has previously been reported that 10 mg/kg of VU0360172 is effective in a rodent model of epilepsy (D’Amore et al., 2014) without producing any behavioural side effects, we wanted to investigate if lower doses of the PAMs would reverse the NOR deficits in the scPCP model. There were no significant differences in the exploration time of 2 identical objects for any group (Figure
2A). In the retention phase, a 2-way ANOVA revealed no significant interaction between treatment with VU compounds and object exploration in scPCP rats: the scPCP-induced impairment in NOR was not reversed by either VU0409551 or VU0360172 (0.05 and 1mg/kg; Figure 2B). The discrimination index in the scPCP rats was also not significantly increased by VU0409551 or VU0360172 (0.05 and 1mg/kg; Figure 2C). Locomotor activity, as assessed by the total number of line crossings in both trials, was not significantly affected by either of the VU compounds (Figure 2D), and there was also no significant effect of drug treatment on total exploration time in scPCP animals in either the acquisition or retention trials (Table 1, Supplementary material). Thus, these low doses of the mGlu5 receptor PAMs were ineffective in reversing the NOR deficits.

**Insert Figure 2 here**

3.22 Cohort 2 (10 and 20mg/kg of mGlu5 receptor PAMs)

We next investigated the effects of the acute administration of 10 and 20mg/kg of VU0409551 and VU0360172. There was no significant effect of VU0409551 or VU0360172 on exploration time of two identical objects during the acquisition phase (Fig 3A). In the retention phase, a 2-way ANOVA revealed a significant interaction between treatment with VU compounds and object exploration in scPCP rats (F(4,112) = 9.214; P<0.0001). The scPCP-induced impairment in NOR was reversed by VU0409551 at 10mg/kg (t(16)=6.575; P=0.000006) but not 20mg/kg, and VU0360172 at both 10mg/kg (t(14)=4.088; P=0.001107) and 20mg/kg (t(16)=3.568; P=0.002568; Figure 3B). The reduction in discrimination index in the scPCP rats was significantly increased by administration of VU0409551 at 10mg/kg (t(32)=7.935; P<0.0001) and 20mg/kg (t(33)=3.792; P=0.0006), and VU0360172 at 10mg/kg (t(31)=6.397; P<0.0001) and 20mg/kg (t(32)=4.865; P<0.0001; Figure 3C). Locomotor activity, as assessed by the total number of line crossings in both trials, was significantly affected by drug treatment (F(5,79)=5.244; P=0.0003). Locomotor activity was significantly reduced in rats treated with 20mg/kg of VU0409551 (t(32)=3.761; P=0.0007) and VU0360172 (t(31)=3.617; P=0.001), and 10mg/kg of VU0360172 (t(30)=2.273; P=0.0303) relative to vehicle-treated animals (Figure 3D). Analyses also revealed a significant difference in total exploration time in the acquisition trial following treatment with VU0409551 at 10mg/kg (t(32)=2.636; P=0.0128) and 20mg/kg (t(33)=3.547; P=0.0012) and VU0360172 at 10mg/kg (t(31)=2.709; P=0.0109) compared with scPCP (Table 2, Supplementary material). A significant difference in total exploration time in the retention trial was also found between scPCP- and VU0360172-treated rats at 10mg/kg (t(31)=2.743; P=0.01). Therefore, at these concentrations both PAMs reversed the deficits in the NOR but there was evidence for some sedation (particularly at 20mg/kg).

**Insert Figure 3 here**
3.3 mGlu5 receptor-mediated signalling in scPCP rats treated with mGlu5 receptor PAMs

We used the PFC of rats that had previously undergone the scPCP paradigm to investigate the signalling pathways activated by the two PAMs stimulating the mGlu5 receptor. We measured the mGlu5R-induced activation of PI-3K and MAPK pathways by western blot analysis, using phospho-specific antibodies recognising the phosphorylated and hence activated forms of AKT and ERK1/2 respectively.

3.31 PI-3K pathway

We investigated the effect of VU0360172 and VU0409551 on PI-3K pathway by measuring the phosphorylated form of AKT, p-AKT by western blot. Activation of AKT affects numerous downstream targets of mGlu5 receptor activation, including proteins that regulate translation (for example, mTOR). Prefrontal cortex samples from the scPCP group showed significantly elevated p-AKT expression relative to samples from the vehicle-treated group (1mg/kg: t(20)=5.584; P=0.0041; 10mg/kg (t(20)= 8.333; P<0.0001; Figure 4). At 1mg/kg neither of the two PAMs had a significant effect on p-AKT expression (VU0409551: t(20)=2.348; P=0.0697; VU0360172: t(20)=3.294; P=0.1248; Figure 4). However, at 10mg/kg, VU0409551 significantly decreased p-AKT relative to the scPCP group (t(20)=4.092; P=0.0411; Figure 4). Although VU0360172 did not significantly reduce the p-AKT the expression of p-AKT was not different to that in VU0409551. Thus, although not reaching significance, VU0360172 had similar effects on p-AKT expression as VU0409551.

3.32 MAPK pathway

In parallel to PI-3K, we studied the effect of the two PAMs on MAPK pathway, by measuring p-MAPK by western blot. Similar to p-AKT, the scPCP group showed significantly elevated p-MAPK expression relative to vehicle-treated samples (1mg/kg: t(20)=4.714; P=0.0161; 10mg/kg: t(20)=4.990; P=0.0105; Figure 5). At 1mg/kg neither of the two PAMs had a significant effect on p-MAPK expression (VU0409551: t(20)=3.281; P=0.0126; VU0360172: t(20)=3.137; P=0.0152; Figure 5). However, at 10mg/kg, VU0360172 significantly decreased p-MAPK relative to the scPCP group (t(20)=4.961; P=0.0109; Figure 5).

Thus, expression of both p-AKT and p-MAPK were elevated in the prefrontal cortex of scPCP model rats which may contribute to the deficits in NOR. These increases in expression were reduced by individual PAMs at higher doses (10 mg/kg) which may play a role in the effects on NOR deficits.

**Insert Figure 4 here**
4. Discussion

Here we have directly compared, for the first time, the efficacy of two mGlu5 receptor PAMs, with potentially different signalling mechanisms, in restoring recognition memory deficits in the sub-chronic PCP (scPCP) model of CIAS. We have also investigated changes in mGlu5 receptor signalling in the scPCP model and the effects of the two PAMs. Although both PAMs reversed scPCP-induced impairments in NOR at 10 mg/kg, they appeared to have slightly different effects on the scPCP-induced increased in AKT and MAPK phosphorylation in the PFC. VU0409551 induced a significant decrease in AKT phosphorylation, whereas VU0260172 had this effect on p-MAPK levels. These data support an important role for these signalling pathways in improving cognitive function in this model.

As expected from previous studies, scPCP animals exhibited significant impairment in NOR relative to controls treated with vehicle (Grayson et al., 2015). Female animals were exclusively used in this study because female rats demonstrate a greater sensitivity to the behavioural effects of PCP and superior performance in cognitive tasks and social behaviour testing compared to male rats (Grayson et al., 2007; Sutcliffe et al., 2007; Wessinger, 1995). The short, 1-minute inter-trial interval (ITI) was selected to specifically probe functioning of the PFC, which is evidenced to be responsible for recognition memory following an ITI of less than 5 minutes. Conversely, novel object recognition at relatively long ITIs (24 hours) is associated with hippocampal activity (Hammond et al., 2004; reviewed by Dere et al., 2007). Animals with functional cognitive abilities are expected to explore the novel object for significantly longer in the retention trial due to the storage, consolidation and retrieval of recognition memory (Dere et al., 2007). Conversely, spending an equal amount of time exploring both the novel and familiar object is indicative of a memory impairment (Mathiasen and DiCamillo, 2010). The significant reduction in the discrimination index of scPCP vs. vehicle-treated rats therefore supports the hypothesis that scPCP mimics CIAS. McLean et al (2017) links these scPCP-induced cognitive deficits to the absence of a PFC dopamine increase during the NOR retention trial that is exhibited by vehicle controls.

Although not significantly affected by the lower doses of the mGlu5 receptor PAMs, the scPCP-induced impairment in NOR was successfully reversed by VU0409551 at 10 mg/kg (but not 20 mg/kg) and VU0360172 at both 10 and 20 mg/kg, along with a significant attenuation in discrimination index scores. This implies that these compounds are effective in restoring functional cognitive abilities, with the lack of effect at lower doses demonstrating a dose-response relationship. However, it should be noted that locomotor activity was significantly reduced in rats treated with the highest dose of both compounds relative to vehicle-treated
animals, suggesting that sedative effects may accompany the cognitive improvement at 20 mg/kg. Similar effects have been previously demonstrated by the application of cariprazine (D₁/D₂ receptor partial agonist) in the scPCP model, with the highest dose tested inducing mild sedative effects in the NOR paradigm (Neill et al., 2016). There is considerable evidence to support the hypothesis that positive modulation of the mGlu5 receptor is a promising therapeutic strategy for treating CIAS. At a genetic level, two variants in GRM5 (encoding the mGlu5 receptor) have been associated with cognitive impairments and right hippocampal volume reduction in schizophrenia patients (Matosin et al., 2018). In terms of receptor activity, recent data from Brambilla et al (2020) link lower mGlu5 receptor binding potential in male schizophrenia patients with greater negative symptoms and worse cognitive performance. Preclinically, the selective mGlu5 receptor antagonist 2-methyl-6(phenylethyl)-pyridine (MPEP) potentiates impaired cognition in the PCP animal model (Campbell et al., 2004).

In our experimental conditions, the beneficial effects of the PAMS on scPCP-induced cognitive impairment are accompanied by at least partial reversal of the abnormally elevated levels of p-MAPK and p-AKT in the PFC. Implication of this brain region in recognition memory deficits have been demonstrated by human fMRI studies showing disrupted PFC activation to impair selective attention and subsequent recognition memory (Rauss et al, 2011; Zanto et al., 2011). Schizophrenia patients also exhibit disruption in PFC GABA-driven neural synchrony, attention and working memory (Gonzalez-Burgos et al., 2010). The PFC is a region of particular interest in the scPCP model, with PCP reported to activate discrete brain regions including the PFC, and excessive PFC glutamate activity resulting from NMDAR blockade (McClatchy et al., 2016). In addition, an in vivo microdialysis technique revealed NMDAR antagonism by PCP to increase extracellular dopamine levels in the PFC (Hondo et al., 1994).

Postmortem studies have strongly associated dysfunction of frontal cortical Akt and MAPK signalling pathways to the pathophysiology of schizophrenia. Kyosseva et al. (1999) showed MAPK-associated proteins and phosphoproteins to be abnormally expressed in the anterior cingulate and dorsolateral PFC, whilst Kunii et al. (2021) reported elevated Akt expression in the PFC of schizophrenia patients relative to controls. Data on the effect of PCP treatment on p-AKT and p-MAPK signalling seem somewhat controversial, as they strictly depend on experimental conditions. Enomoto et al. (2005) demonstrate that chronic PCP stimulation of mice induces an increase in p-MAPK. In hippocampal slices from these PCP-treated mice, p-MAPK stimulation by drugs as NMDA, Glycine and spermidine is also impaired. Our data confirm and extend these findings by showing that in rat PFC, PCP-increased p-MAPK and p-AKT are selectively modulated by 2 different mGlu5 receptors PAMS. The molecular mechanism underlying these effects remains to be elucidated, nevertheless, a link between these PFC intracellular signalling cascades and cognition is supported by previous investigations using schizophrenia animal models. Koo et al. (2020) reported both MK-801-induced NOR deficits and upregulated Akt phosphorylation to be restored by antipsychotic drugs.

In the context of such evidence, this study is not only significant in supporting a role for dysfunctional signalling cascades in the cognitive deficits of schizophrenia, but also in providing a possible mechanism underlying the efficacy of mGlu5 receptor PAMS in restoring cognition. Notably, the differential effects of
VU0409551 and VU0360172 on expression of p-AKT and p-MAPK respectively implies a specificity of these compounds which may enable them to modulate the mGlu5 receptor whilst inducing fewer side effects. These results could be explained by the differential stimulation of mGlu5 receptor-associated signalling pathways by these compounds, with VU0360172 reportedly activating both Gaq- and Gβγ- mediated receptor signalling, while VU0409551 preferentially stimulating the Gaq- mediated counterpart (Sengmany et al., 2017).

These promising data support the efficacy of mGlu5 receptor PAMs as a possible therapeutic intervention for CIAS and warrant further investigation into the role of mGlu5 receptor-associated signalling pathways in improving cognitive function. This study provides a strong basis for future work to further neurobiological understanding of CIAS. Specifically, we recommend follow-up work to assess the effects of these compounds upon inflammation and parvalbumin levels, which may underly the beneficial impacts on cognition, and utilise chronic PAM administration to distinguish acute from long-term consequences. Ultimately, deeper insight into the mechanisms underlying mGlu5 receptor PAM-induced alleviation of cognitive deficits associated with schizophrenia will enable the mGlu5 receptor to be modulated with enhanced specificity and fewer side effects. Considering the strong association of patient functional recovery with cognitive deficits, such effective pharmacological targeting is an imperative step toward improving quality of life for patients debilitated by this unmet clinical need.

**Author contribution section**

Jessica Brown: Investigation, Formal analysis, Writing – Original Draft; Luisa Iacovelli: Investigation, Formal analysis; Gabriele Di Cicco: Investigation; Ben Grayson: Methodology, Resources; Lauren Rimmer: Investigation; Jennifer Fletcher: Investigation, Joanna Neill: Funding acquisition, Supervision, Project Administration, Methodology, Conceptualisation; Richard Ngomba: Supervision, Project Administration, Conceptualisation, Writing – Review & Editing; Mark Wall: Conceptualisation, Writing – Review & Editing; Michael Harte: Funding acquisition, Project administration, Supervision, Methodology, Conceptualisation, Writing – Review & Editing, Resources

**Acknowledgments**

Jessica Brown is a DTP PhD student funded by the MRC.

**Disclosure**

None of the authors have any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
References


Jentsch, J.D., Roth, R.H., 1999. The neuropsychopharmacology of phenycyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201–225. https://doi.org/10.1016/S0893-133X(98)00060-8


**Figure legends**

**Figure 1.** Experimental protocol and confirmation that novel object recognition is disrupted in the sub-chronic PCP (scPCP) model

A. Experimental protocol. B. Schematic illustrating the Novel object recognition (NOR) test protocol. There is a 3-minute acquisition trial (with two identical objects) and then a 3-minute retention trial (with two non-identical objects) separated by a 1-minute inter-trial interval (ITI). C, D. The effect of scPCP treatment (2 mg/kg, i.p. twice daily for seven days, followed by a 3-week washout period) on the exploration time (s) of a familiar object and a novel object in the 3 min retention trial. Data are expressed as mean ± S.E.M (n=6-30 per group) and were analysed by ANOVA and post-hoc Student's t-test. ****P<0.0001; Significant increase in time spent exploring the novel object compared to the familiar object. E. The effect of scPCP treatment on the discrimination index (DI). Data are expressed as the mean ± S.E.M (n=6-30 per group) and were analysed using ANOVA followed by post-hoc LSD t-test. ****P<0.0001; Significant reduction in DI compared to vehicle. F. The effect of scPCP treatment on total number of line crossings in the acquisition and retention trials. Data are expressed as the mean ± S.E.M (n=6-30 per group) and were analysed using ANOVA followed by post-hoc LSD t-test.

**Figure 2.** Low doses (0.05/1 mg/kg) of VU0409551 and VU0360172 do not reverse the effect of scPCP on NOR performance.
A, B. Acute treatment with low doses of VU0409551 (0.05 and 1 mg/kg) and VU0360172 (0.05 and 1 mg/kg) were unable to reverse the effect of scPCP (2 mg/kg, i.p. twice daily for seven days, followed by a 6-week washout period) on the exploration time (s) of a familiar object and a novel object in the 3 min retention trial. Data are expressed as mean ± S.E.M (n=11-20 per group) and were analysed by ANOVA and post-hoc Student’s t-test. ****P<0.0001; Significant increase in time spent exploring the novel object compared to the familiar object. C. The effect of acute treatment with VU0409551 (0.05 and 1 mg/kg) and VU0360172 (0.05 and 1 mg/kg) in scPCP treated rats on the discrimination index (DI). Data are expressed as the mean ± S.E.M (n=11-20 per group) and were analysed using ANOVA followed by post-hoc LSD t-test. ****P<0.0001; Significant reduction in DI compared to vehicle. D The effect of acute treatment with VU0409551 (0.05 and 10 mg/kg) and VU0360172 (0.05 and 1 mg/kg) in scPCP treated rats on total number of line crossings in the acquisition and retention trials. Data are expressed as the mean ± S.E.M (n=11-20 per group) and were analysed using ANOVA followed by post-hoc LSD t-test. 

Figure 3. Higher doses (10/20 mg/kg) of VU04091551 and VU0360172 successfully reverse the effect of scPCP on NOR performance.

A, B. The ability of acute treatment with VU0409551 (10 and 20 mg/kg) and VU0360172 (10 and 20 mg/kg) to reverse the effect of scPCP (2 mg/kg, i.p. twice daily for seven days, followed by a 6-week washout period) on the exploration time (s) of a familiar object and a novel object in the 3 min retention trial. Data are expressed as mean ± S.E.M (n=8-25 per group) and were analysed by ANOVA and post-hoc Student’s t-test. **P<0.01, ***P<0.001, ****P<0.0001; Significant increase in time spent exploring the novel object compared to the familiar object. C. The effect of acute treatment with VU0409551 (10 and 20 mg/kg) and VU0360172 (10 and 20 mg/kg) in scPCP treated rats on the discrimination index (DI). Data are expressed as the mean ± S.E.M (n=8-25 per group) and were analysed using ANOVA followed by post-hoc LSD t-test. ****P<0.0001; Significant reduction in DI compared to vehicle. $$$ P<0.0001, $$ P<0.001; Significant increase in DI compared to scPCP. D. The effect of acute treatment with VU0409551 (10 and 20 mg/kg) and VU0360172 (10 and 20 mg/kg) in scPCP treated rats on total number of line crossings in the acquisition and retention trials. Data are expressed as the mean ± S.E.M (n=8-25 per group) and were analysed using ANOVA followed by post-hoc LSD t-test. *P<0.05, **P<0.01, ***P<0.001; Significant decrease in the total number of line crossings compared to vehicle.

Figure 4. The effect of of VU0409551 and VU0360172 on p-AKT expression in scPCP rats.

Acute treatment with VU0409551 and VU0360172 at A. 1mg/kg and B. 10mg/kg in scPCP treated rats (2 mg/kg, i.p. twice daily for seven days, followed by a 6-week washout period) on p-AKT optical density (OD) in PFC tissue. Data are expressed as the mean ± S.E.M (n=6 per group) and were analysed using the Tukey’s multiple comparison test.**P<0.01, ****P<0.0001; Significant increase in OD levels compared to vehicle group. *P<0.01; Significant decrease in OD levels compared to PCP group.
**Figure 5.** The effect of VU0409551 and VU0360172 on p-MAPK expression in scPCP rats.

Acute treatment with VU0409551 and VU0360172 at A. 1mg/kg and B. 10mg/kg in scPCP treated rats (2 mg/kg, i.p. twice daily for seven days, followed by a 6-week washout period) on p-MAPK optical density (OD) levels in PFC tissue. Data are expressed as the mean ± S.E.M (n=6 per group) and were analysed using the Tukey’s multiple comparison test. *P<0.05; Significant increase in the OD levels compared to vehicle. *P<0.05; Significant decrease in OD levels compared to PCP group.

**Table 1. Effect of low doses of VU0409551 and VU0360172 on total exploration time.**

The effect of acute treatment with VU0409551 (0.05 and 1 mg/kg) and VU0360172 (0.05 and 1 mg/kg) in scPCP treated rats (2 mg/kg, i.p. twice daily for seven days, followed by at least 7-day washout period) on the total exploration time (s) in the acquisition and retention trials. Data are expressed as the mean ± S.E.M (n=11-20 per group) and were analysed using ANOVA followed by post-hoc LSD t-test.

**Table 2. Effect of high doses of VU0409551 and VU0360172 on total exploration time.**

The effect of acute treatment with VU0409551 (10 and 20 mg/kg) and VU0360172 (10 and 20 mg/kg) in scPCP treated rats (2 mg/kg, i.p. twice daily for seven days, followed by a 6-week washout period) on the total exploration time (s) in the acquisition and retention trials. Data are expressed as the mean ± S.E.M (n=8-25 per group) and were analysed using ANOVA followed by post-hoc LSD t-test.
**Figure 1**

A. Sub-chronic phencyclidine administration (2mg/kg intraperitoneally, twice daily for 7 days)

B. Acquisition trial → Retention trial

C. Acquisition trial

D. Retention trial

E. Discrimination index

F. Line crossings
Figure 2

A  Acquisition trial

B  Retention trial

C  Discrimination index

D  Line crossings
Figure 3

A. Acquisition trial

B. Retention trial

C. Discrimination index

D. Line crossings
Figure 4

A. Low dose (1mg/kg)

B. High dose (10mg/kg)
Figure 5
Supplementary material

Table 1. The effect of acute treatment with VU0409551 (0.05 & 1 mg/kg) and VU0360172 (0.05 & 1 mg/kg) in scPCP treated rats on total exploration time in the acquisition and retention trials.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Acquisition trial total exploration time (s)</th>
<th>Retention trial total exploration time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle + Vehicle</td>
<td>22.2 ± 1.62</td>
<td>19.4 ± 1.54</td>
</tr>
<tr>
<td>scPCP + Vehicle</td>
<td>17.12 ± 1.86</td>
<td>15.85 ± 1.81</td>
</tr>
<tr>
<td>VU0360551 0.05mg/kg</td>
<td>22.8 ± 1.92</td>
<td>32.3 ± 2.84</td>
</tr>
<tr>
<td>VU0360172 0.05mg/kg</td>
<td>17.9 ± 1.4</td>
<td>16.6 ± 1.46</td>
</tr>
<tr>
<td>VU0409551 1mg/kg</td>
<td>22.3 ± 1.97</td>
<td>23.2 ± 2.56</td>
</tr>
<tr>
<td>VU0360172 1mg/kg</td>
<td>16.7 ± 1.95</td>
<td>17.8 ± 3.24</td>
</tr>
</tbody>
</table>

Table 2. The effect of acute treatment with VU0409551 (10 & 20 mg/kg) and VU0360172 (10 & 20 mg/kg) in scPCP treated rats on total exploration time in the acquisition and retention trials.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Acquisition trial total exploration time (s)</th>
<th>Retention trial total exploration time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle + Vehicle</td>
<td>28.7 ± 1.99</td>
<td>24.5 ± 1.9</td>
</tr>
<tr>
<td>scPCP + Vehicle</td>
<td>29.4 ± 1.88</td>
<td>24.5 ± 2.12</td>
</tr>
<tr>
<td>VU0409551 10mg/kg</td>
<td>38.9 ± 2.9</td>
<td>29.9 ± 2.33</td>
</tr>
<tr>
<td>VU0360172 10mg/kg</td>
<td>39.03 ± 2.09</td>
<td>36.5 ± 4.13</td>
</tr>
<tr>
<td>VU0409551 20mg/kg</td>
<td>17.6 ± 2.35</td>
<td>21.8 ± 3.51</td>
</tr>
<tr>
<td>VU0360172 20mg/kg</td>
<td>26.1 ± 1.56</td>
<td>26.9 ± 2.39</td>
</tr>
</tbody>
</table>
Figure 4. Full p-AKT western blot images

Low dose (1mg/kg)

High dose (10mg/kg)

Figure 5. Full p-MAPK western blot images.

In the western blots below, please note that due to low availability of anti-p-AKT antibody during the pandemic, 2 membranes were cut as much as possible and probed together, to save antibody.